Lead Product(s): Penicillin G Potassium
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Proteon Therapeutics
Deal Size: $42.5 million Upfront Cash: Undisclosed
Deal Type: Merger January 09, 2020
ArTara therapeutics completes merger with proteon therapeutics. The net proceeds from this financing will fund development of ArTara’s lead assets, TARA-002 and intravenous (IV) choline chloride.